Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Chewy Inc (CHWY) vs 10X Genomics Inc (TXG) Price & Performance

10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Chewy Inc vs 10X Genomics Inc — how do they compare? Chewy Inc trades at $22.24 (market cap $9.20B), while 10X Genomics Inc trades at $57.71 (market cap $7.61B). The key difference: Chewy Inc is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, Chewy Inc nearer its low. Which is the better fit depends on your goals.

CHWYTXG
Market Cap
$9.20B$7.61B
Sector
Consumer CyclicalHealth
52-Week High
$42.33$58.57
52-Week Low
$17.51$11.34
Enterprise Value
$9.16B$7.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Chewy Inc

Chewy (CHWY) trades at $22.59, down 3.99% on the day, reflecting near-term bearish technical pressure. The stock shows strong fundamental progress with revenue climbing to $11.86B in 2025 and net income surging to $392.74M, marking a significant profitability turnaround. Recent earnings beats in Q3 2025 and Q1 2026 contrast with a Q4 2025 miss, indicating volatility. Analyst sentiment remains overwhelmingly positive with an 81.58% buy rating and a $33.82 consensus price target, suggesting substantial upside potential from current levels.

The investment outlook for CHWY is constructive, driven by robust revenue growth, expanding margins, and strong analyst conviction. Key opportunities include the company's dominant position in the pet care e-commerce space and its high customer loyalty through the Autoship subscription model. Primary risks involve competitive pressures from larger retailers, execution challenges in integrating veterinary services, and sensitivity to consumer spending trends. The stock presents a growth opportunity but requires monitoring of quarterly execution against high expectations.

10X Genomics Inc

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.

Returns comparison

Trailing returns across standard periods

About Chewy Inc

Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.

Read more on CHWY

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG